Diagnostic Insights into Chronic-inflammatory Demyelinating Polyneuropathies

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2018 Oct 12

PMID 30306076

Citations 9

Authors

Johannes J Roggenbuck

Joseph Boucraut

Emilien Delmont

Karsten Conrad

Dirk Roggenbuck

Affiliations

Soon will be listed here.

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated neuropathy with demyelination of nerve fibers as leading morphological feature. The course of disease can be chronic progressive or remitting relapsing. Whereas for acute immune-mediated neuropathies several serological markers have been identified and used successfully in clinical routine, the serological diagnosis of chronic variants such as CIDP has not yet been evolved satisfactory. The typical CIDP and its various atypical variants are characterized by a certain diversity of clinical phenotype and response to treatment. Thus, diagnostic markers could aid in the differential diagnosis of CIDP variants and stratification of patients for a better treatment response. Most patients respond well to a causal therapy including steroids, intravenous immunoglobulins and plasmapheresis. Apart from electrophysiological and morphological markers, several autoantibodies have been reported as candidate markers for CIDP, including antibodies against glycolipids or paranodal/nodal molecules. The present review provides a summary of the progress in autoantibody testing in CIDP and its possible implication on the stratification of the CIDP variants and treatment response.

Citing Articles

Chronic Inflammatory Demyelinating Polyneuropathy: A Narrative Review of a Systematic Diagnostic Approach to Avoid Misdiagnosis.

Roman-Guzman R, Martinez-Mayorga A, Guzman-Martinez L, Rodriguez-Leyva I Cureus. 2025; 17(1):e76749.

PMID: 39897200 PMC: 11785518. DOI: 10.7759/cureus.76749.

Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.

Dziadkowiak E, Nowakowska-Kotas M, Ralowska-Gmoch W, Budrewicz S, Koszewicz M Int J Mol Sci. 2023; 24(11).

PMID: 37298132 PMC: 10252615. DOI: 10.3390/ijms24119180.

Principles of Therapeutic Apheresis in Neurological Disease.

Strasser E Transfus Med Hemother. 2023; 50(2):88-97.

PMID: 37066058 PMC: 10091019. DOI: 10.1159/000529463.

Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? - A Pilot Study.

Koszewicz M, Mulak A, Dziadkowiak E, Budrewicz S Front Hum Neurosci. 2021; 15:733070.

PMID: 34867240 PMC: 8636096. DOI: 10.3389/fnhum.2021.733070.

Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.

Mansour M, Rachdi A, Baradai N, Kacem A, Bedoui I, Mrissa R Neurol Sci. 2021; 43(1):565-571.

PMID: 33945035 DOI: 10.1007/s10072-021-05153-x.

References

Querol L, Devaux J, Rojas-Garcia R, Illa I . Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017; 13(9):533-547. DOI: 10.1038/nrneurol.2017.84. View

Attarian S, Boucraut J, Hubert A, Uzenot D, Delmont E, Verschueren A . Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry. 2009; 81(1):61-4. DOI: 10.1136/jnnp.2009.185736. View

Burnor E, Yang L, Zhou H, Patterson K, Quinn C, Reilly M . Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology. 2017; 90(1):e31-e38. PMC: 5754648. DOI: 10.1212/WNL.0000000000004773. View

Giannotta C, Di Pietro D, Gallia F, Nobile-Orazio E . Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test?. Eur J Neurol. 2015; 22(5):879-82. DOI: 10.1111/ene.12658. View

Pang S, Chan K, Mak W, Kung M, Lee C, Tsoi T . Single-nucleotide polymorphism of transient axonal glycoprotein-1 and its correlation with clinical features and prognosis in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2012; 17(1):72-5. DOI: 10.1111/j.1529-8027.2012.00380.x. View

Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D . Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015; 2(10):960-71. PMC: 4603379. DOI: 10.1002/acn3.248. View

Chiba A, Kusunoki S, Shimizu T, Kanazawa I . Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992; 31(6):677-9. DOI: 10.1002/ana.410310619. View

Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon M . Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing acute-onset chronic from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014; 51(6):846-52. DOI: 10.1002/mus.24484. View

Merkies I, Schmitz P, van der Meche F, Samijn J, van Doorn P . Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve. 2002; 25(3):370-7. DOI: 10.1002/mus.10045. View

10.

Man Ng J, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T . Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012; 79(23):2241-8. PMC: 3542349. DOI: 10.1212/WNL.0b013e31827689ad. View

11.

Fraussen J, Claes N, de Bock L, Somers V . Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev. 2014; 13(11):1126-37. DOI: 10.1016/j.autrev.2014.07.002. View

12.

Ruts L, Drenthen J, Jacobs B, van Doorn P . Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010; 74(21):1680-6. DOI: 10.1212/WNL.0b013e3181e07d14. View

13.

Mahdi-Rogers M, Hughes R . Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2013; 21(1):28-33. DOI: 10.1111/ene.12190. View

14.

Roggenbuck D, Borghi M, Somma V, Buttner T, Schierack P, Hanack K . Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016; 18(1):111. PMC: 4875598. DOI: 10.1186/s13075-016-1018-x. View

15.

Nobile-Orazio E, Giannotta C, Briani C . Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol. 2009; 219(1-2):119-22. DOI: 10.1016/j.jneuroim.2009.11.012. View

16.

Dyck P, Lais A, Ohta M, BASTRON J, Okazaki H, GROOVER R . Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975; 50(11):621-37. View

17.

Kleyman I, Brannagan 3rd T . Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep. 2015; 15(7):47. DOI: 10.1007/s11910-015-0563-z. View

18.

Caudie C, Quittard Pinon A, Bouhour F, Vial C, Garnier L, Fabien N . Comparison of commercial tests for detecting multiple anti-ganglioside autoantibodies in patients with well-characterized immune-mediated peripheral neuropathies. Clin Lab. 2014; 59(11-12):1277-87. DOI: 10.7754/clin.lab.2013.121116. View

19.

Kwa M, van Schaik I, Brand A, Baas F, Vermeulen M . Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol. 2001; 116(2):220-5. DOI: 10.1016/s0165-5728(01)00307-1. View

20.

Ishibashi T, Dupree J, Ikenaka K, Hirahara Y, Honke K, Peles E . A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci. 2002; 22(15):6507-14. PMC: 6758132. DOI: 20026705. View